In tumors, PD-L1 is expressed on both tumor cells15 and immune cells16, and preclinical data revealed that functional Fc could enhance the anti-tumor activity of PD-L1 antibodies via the ADCC against the PD-L1 positive immune-suppressive myeloid cells17 and tumor cells18. Here, CD274 is linked to neoplasm.